Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function
Completed · Phase 1
Conditions studied: Kidney Diseases, Hyponatremia
In brief
A study to compare a conivaptan PK in subjects with mild or moderate kidney function impairment to subjects with normal kidney function after a 48-hour continuous infusion of conivaptan.
Key facts
- Study ID
- NCT00887627
- Run by
- Cumberland Pharmaceuticals
- People needed
- 25
- Starts
- 2009-04-01
- Expected to finish
- 2010-07-01
- Last updated by the study team
- 2014-05-02
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Weighs at least 45 kg
- Body mass index between 18 and 40 kg/m2 inclusive
- Must be in good health other than renal function impairment and related stable diseases for the renal impaired subjects
- Must have a screening and pre-dose estimated glomerular filtration rate (GFR) that corresponds with the level of renal impairment based on the abbreviated Modification of Diet in Renal Disease (MDRD) formula
- Female subject of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test, utilizes adequate contraceptive methods while in this study or may be surgically sterile and/or two years post menopausal
You may not qualify if…
- Subject is known to be HIV positive or has HIV antibodies
- Has clinically significant history or presence of illness, medical condition, or laboratory abnormality
- Is Hepatitis positive
- Subject with renal impairment has not been on a stable dose of concomitant medications for at least 4 weeks prior to start of study and/or dose changes are likely during the study
- History of substance abuse within 6 months prior to screening
- Has clinically significant history or presence of psychiatric illness, malignancy, or immunodeficiency syndrome
- Has abnormal liver function tests (ALT, AST, and/or bilirubin)
- Has had a blood transfusion or donated/lost more than 450ml of blood within 56 days of study drug administration or has donated plasma within 7 days prior to study drug administration
Where it is running
- Study site — Anaheim, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.